The FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This acceptance marks a key advancement for the company, with a PDUFA action date set for January 6, 2027. The application is backed by positive Phase 2/3 trial data showing a 58.2% 12-month disease-free survival rate. ImmunityBio's stock rose over 8% in premarket trading following the news, reflecting strong investor confidence in the drug's potential.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
